Pfizer Raises Annual Profit and Revenue Forecasts Driven by Eliquis Demand
Pfizer (PFE) has upwardly revised its full-year financial guidance, projecting adjusted earnings per share between $2.95 and $3.05, surpassing previous estimates. The company also raised its annual revenue outlook to a range of $62 billion to $64 billion, driven by robust performance in its non-COVID portfolio. A primary driver for the upgrade is the blood thinner Eliquis, which saw global sales jump 25% due to increased demand and higher net pricing in the U.S. Additionally, oncology medication Padcev reported a significant 55% increase in sales. These gains reflect Pfizer's strategic shift toward newer medications to reduce dependency on pandemic-era COVID-19 products.
Tickers: $PFE
Topics: earnings forecast Eliquis sales pharmaceuticals revenue guidance
Read the full article at Yahoo Finance
Part of the story Pfizer Raises Annual Profit and Revenue Forecasts Driven by Eliquis Demand (6 articles)